Contract manufacturing, royalty and other revenue — Total Revenue
Biogen Contract manufacturing, royalty and other revenue — Total Revenue increased by 63.3% to $246.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 15.8%, from $293.30M to $246.90M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests successful monetization of excess manufacturing capacity or a growing portfolio of licensed intellectual property, while a decrease may indicate expiring royalty agreements or reduced demand for contract services.
Detailed definition
This metric represents the aggregate revenue generated from contract manufacturing services, intellectual property royal...
Peer comparison
Peers in the biopharmaceutical industry often report this under 'Other Revenue' or 'Collaboration and Royalty Revenue,' with variations depending on the extent of their CDMO (Contract Development and Manufacturing Organization) operations.
biib_segment_contract_manufacturing_royalty_and_other_revenue_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $99.00M | $157.80M | $126.20M | $66.10M | $97.90M | $129.50M | $191.60M | $319.10M | $197.50M | $304.20M | $184.60M | $120.80M | $250.20M | $293.30M | $244.60M | $151.20M | $246.90M |
| QoQ Change | — | +59.4% | -20.0% | -47.6% | +48.1% | +32.3% | +48.0% | +66.5% | -38.1% | +54.0% | -39.3% | -34.6% | +107.1% | +17.2% | -16.6% | -38.2% | +63.3% |
| YoY Change | — | — | — | — | -1.1% | -17.9% | +51.8% | +382.8% | +101.7% | +134.9% | -42.1% | -38.8% | -17.8% | +58.9% | +102.5% | -39.6% | -15.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's contract manufacturing, royalty and other revenue — total revenue?
- Biogen (BIIB) reported contract manufacturing, royalty and other revenue — total revenue of $246.90M in Q1 2026.
- How has Biogen's contract manufacturing, royalty and other revenue — total revenue changed year-over-year?
- Biogen's contract manufacturing, royalty and other revenue — total revenue decreased by 15.8% year-over-year, from $293.30M to $246.90M.
- What does contract manufacturing, royalty and other revenue — total revenue mean?
- Total income earned from manufacturing services for other companies, licensing royalties, and other non-core business activities.